Multiple Myeloma & CAR-T Cell Therapy
Meet the Speakers
Saad Usmani, MD, MBA, FACP
Hematologic Oncologist
Chief, Myeloma Service
Memorial Sloan Kettering Cancer Center
Hematologic Oncologist
Chief, Myeloma Service
Memorial Sloan Kettering Cancer Center
Krina Patel, MD, MSc
Associate Professor
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Associate Professor
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Peter Voorhees, MD
Professor of Medicine
Chief, Plasma Cell Disorders Division
Vice Chair for Administration and Clinical Care
Associate Medical Director of Clinical Trials
Department of Hematologic Oncology and Blood Disorders
Levine Cancer Institute, Atrium Health/Wake Forest Baptist
Professor of Medicine
Chief, Plasma Cell Disorders Division
Vice Chair for Administration and Clinical Care
Associate Medical Director of Clinical Trials
Department of Hematologic Oncology and Blood Disorders
Levine Cancer Institute, Atrium Health/Wake Forest Baptist
Program Objectives
Explore multiple myeloma and CAR-T cell therapy
Describe unmet needs in the treatment of patients with relapsed/refractory multiple myeloma
Review CAR-T cell therapy administration and recommendation for the management of AEs
AE, adverse events; CAR-T, chimeric antigen receptor-T cell.
© Janssen Biotech, Inc. 2024 08/24 cp-467365v1